BioWorld Asia

May 28, 2008

New Target Raises Hopes for Future Cancer Vaccines

Amsterdam Molecular Signs CRADA for Gene Therapy

BioAlliance Buys Rights to NovaDel's Ondansetron

Myriad Gets $100M Up Front in European Deal for Flurizan

EU Biosimilar Debate Moves to Use in Clinical Practice

LONDON - With the first generic biologics reaching the market in Europe, the focus has shifted from arguments about how to approve them, to how the products should be used in clinical practice. (BioWorld International) Read More

Daiichi Sankyo Paying $235M For U3's Oncology Pipeline

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...